NCT06874335View on ClinicalTrials.gov

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Solid Tumor
Interventions
DRUG

BHV-1530

BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle

Trial Locations (12)

22031

RECRUITING

Site-102, Fairfax

27710

RECRUITING

Site-115, Durham

29572

RECRUITING

Site-112, Myrtle Beach

32746

RECRUITING

Site-108, Lake Mary

37203

RECRUITING

Site-116, Nashville

48201

RECRUITING

Site-110, Detroit

75039

RECRUITING

Site-101, Irving

77030

RECRUITING

Site-104, Houston

78229

RECRUITING

Site-105, San Antonio

78758

RECRUITING

Site-103, Austin

80218

RECRUITING

Site-107, Denver

84119

RECRUITING

Site-106, West Valley City

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY

NCT06874335 - A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter